MedTrace Logo

Multi-CAR T Cell Therapy for Acute Myeloid Leukemia

NCT03222674 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2026-04-24

No results posted yet for this study

Summary

The purpose of this clinical trial is to assess the feasibility, safety and efficacy of multi-CAR T cell therapy targeting different AML surface antigens in patients with relapsed or refractory acute myeloid leukemia (AML). Another goal of the study is to learn more about the function of the multi-CAR T cells and their persistency in the patients.

Conditions

Interventions

BIOLOGICAL

Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells

Infusion of Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells

Sponsors & Collaborators

  • Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China

    collaborator UNKNOWN

  • Yunnan Cancer Hospital

    collaborator OTHER

  • Shenzhen Geno-Immune Medical Institute

    lead OTHER

Principal Investigators

  • Lung-Ji Chang · Shenzhen Geno-Immune Medical Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-15
Primary Completion
2028-06-30
Completion
2028-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03222674 on ClinicalTrials.gov